Board of Directors
DOUG MANION M.D., FRCP(C)
CHAIRMAN OF THE BOARD / CHIEF EXECUTIVE OFFICER
Dr. Manion has over 20 years of experience in drug development. He was Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at Bristol-Myers Squib (NYSE:BMS) until October 2016. He held leadership roles at BMS overseeing various therapeutic areas, including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GlaxoSmithKline (NYSE: GSK). He started his career at DuPont Pharmaceuticals in 1997. He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa, Canada. He received a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School. Doug also serves on the Board of Directors of Celleron Therapeutics.
DIRECTOR AND CHAIRPERSON
Dr. Doogan is a seasoned drug development executive and life sciences investor with more than 30 years of experience in the global pharmaceutical industry. He joined Pfizer in 1982, where he held a number of senior positions in Research and Development in the U.S., UK and Japan. Dr. Doogan was the clinical development head for what became ZOLOFT, one of the top-selling global products. He retired from Pfizer in 2007 as the Senior VP Head of World Drug Development. Subsequently Dr. Doogan was Head of Research and Development at Amarin where, along with the CEO, he raised $100 million to fund the company's reorganization and portfolio realignment, leading to completion of a Phase 3 program and NDA approval of Vascepa. During his career, Dr. Doogan has engaged in activities to promote excellence in pharmaceutical medicine and sits on the Boards of several biotechnology companies including Chairperson of Biohaven Pharmaceuticals (BHVN: NYSE). Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians of Glasgow and the Faculty of Pharmaceutical Medicine in the UK.
CHARLES G. DRAKE, MD PHD
Dr. Drake is director of genitourinary oncology and associate director for clinical research at the Herbert Irving Comprehensive Cancer Center at New York-Presbyterian / Columbia University. A nationally recognized expert in immunotherapy, Dr. Drake also serves as co-director of Columbia’s Cancer Immunotherapy Programs and on the faculty of CUMC. Previously, Dr. Drake served as the co-director of the Cancer Immunology Program at Johns Hopkins Kimmel Cancer Center, where he was also co-director of the Prostate Cancer Multi-Disciplinary Clinic, and a professor of oncology, urology, and immunology. Dr. Drake is a physician-scientist whose work focuses on understanding and fighting advanced-stage cancers with the immune system. His most recent work has focused on the body’s immunological response to radiation therapy, immunotherapy and anti-tumor vaccines to treat cancer. He received his MD and PhD in immunology from National Jewish Center for Immunology and Respiratory Medicine at the University of Colorado Health Sciences Center. Dr. Drake did his internship and residency in internal medicine, and medical oncology fellowship at Johns Hopkins.
JOHN W. CHILDS
Mr. Childs is the retired Chairman of J.W. Childs Associates, L.P., a private equity firm that he co-founded in 1995. Previously, he was Senior Managing Director of the Thomas H. Lee Company from 1991 to 1995, where he had broad responsibilities for originating, analyzing, negotiating and managing leveraged buyout transactions. For 17 years Mr. Childs held various executive positions in the investment area at the Prudential Insurance Company of America, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. He is currently a Director of Realm, LLC, Biohaven Pharmaceuticals, Kleo Pharmaceuticals, OMAX, JW Childs Asia Equities. Prior to their sale, he was Chairman of the Board of Kosta Browne, Sunny Delight and CHG Healthcare Services. Mr. Childs received his BA from Yale University and MBA from Columbia University.
Mr. Prieb is a technology entrepreneur with over 20 years of experience in business strategy, development, and operations. Prior to co-founding Kleo Pharmaceuticals Inc., he launched, funded, and grew several digital media ventures including Saaspire, Kellogg Media Group, Qiosk.com and JibJab.com. He was a management consultant with The Boston Consulting Group, where he executed strategy and reengineering projects for large banks and financial institutions in Asia. He received his BA from Harvard University Magna Cum Laude and MBA from The Wharton School, University of Pennsylvania.
GREGORY H. BAILEY, MD
Dr. Bailey has spent the last 15 years as an entrepreneur, executive and financier in the healthcare sector. He is currently Chairman of the Board at Portage Biotech Inc. and has served on the Board of Directors for 16 public companies. He is a former director and financier of Medivation Inc. (NASDAQ: MDVN) and co-founder of Ascent Healthcare Solutions, VirnetX Inc internet security (AMEX: VHC) and Duramedic Inc., a medical products company. Prior posts within the investment and financial services sector included serving as Managing Director of Gilford Securities Inc., Managing Director of Knightsford Bank Corp, Senior Managing Director positions at Viscogliosi Brothers and the LXV Prosperity Fund, founder and General Manager of the ABN Private Equity Fund, co-founder of EuroAmerican Mercantile Bancorp, and co-founder and CEO of V-Fund Investments, Ltd. Dr. Bailey received his MD from the University of Ontario before practicing for ten years as an emergency room physician.
VLAD CLORIC, MD
Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. At Bristol-Myers Squibb, Dr. Coric worked across therapeutic areas including neuroscience, virology, oncology and immuno-oncology, most recently serving as immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), and YERVOY® (Ipilimumab; anti-CTLA-4). Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.
Mr. Eklund is a Managing Director at J.W. Childs Associates focusing on venture capital investments. The Childs venture portfolio includes investments in BioHaven Pharmaceuticals (NYSE: BHVN), Kleo Pharmaceuticals, Melinta Therapeutics, Omax Health, Inc, Stemedica Cell Technologies and Basin Holdings. Prior to joining J.W. Childs, Mr. Eklund was Managing Director/Head of Corporate Strategy and Mergers & Acquisitions at New York Life Investment Management. He was a Director at Berkshire Capital Corporation; Furman Selz LLC and Merrill Lynch & Co. He is currently Chairman of Omax Health, Inc. Mr. Eklund received an A.B. from Harvard College and an M.B.A. from Harvard Business School
DAVID A. LEWIN, PHD
Dr. Lewin has more than 14 years of business development and licensing experience in life sciences with Yale’s Office of Cooperative Research (OCR) and has spent more than 20 years successfully managing scientific-based business alliances with pharmaceutical leaders in the U.S., Europe and Asia. He has scientific expertise in pharmaceuticals, biomarkers, cell biology, genomics and proteomics in many disease areas as well as clinical biomarker discovery, development, validation and clinical implementation experience. Dr. Lewin has been instrumental in establishing and growing new ventures arising from Yale technologies, including Kleo Pharmaceuticals, Biohaven Pharmaceuticals, Osmol Therapeutics, Inozyme Pharma, and Kolltan Pharmaceuticals. Prior to his work at OCR, Dr. Lewin was a group leader for CuraGen Corporation in collaborative research/alliance management and biomarker discovery and development. Dr. Lewin holds a BA in Biochemistry and Cell Biology from the University of California San Diego and a PhD in Cell Biology from Yale.
DAVID SPIEGEL, MD PHD
Dr. Spiegel is a Professor of Chemistry and Pharmacology at Yale University, where he heads the Spiegel Research Group. He has co-authored over 50 peer-reviewed publications and is an inventor on over a dozen patents, including those related to Kleo's ARM, SyAM and MATE platforms. He has been recognized with various awards and honors, including the NIH Director's New Innovators Award, the Ellison Medical Foundation New Scholar Award in Aging Research, the Bill and Melinda Gates Foundation Grand Challenges Explorations Award, an Alfred P. Sloan Foundation Fellowship, an Arthur C. Cope Early Career Scholars Award, and others. David received a BA from Harvard University and a MD PhD from Yale University.
Mr. Wagner evaluates investment opportunities, structures new investments and monitors portfolio companies at Connecticut Innovations. Previously, Mr. Wagner held a variety of scientific and operational management positions in research and development, technology assessment and implementation of next-generation scientific technologies at CuraGen in support of the Company’s development of its protein, antibody-drug conjugates and small-molecule therapeutics. Dan received a BS in Biology from the University of Dayton and from Quinnipiac University, a MHS in Biomedical Sciences and a MBA.